RHB Investment Research Reports

Hartalega - Upbeat on Prospects Despite Near-Term Headwinds

rhbinvest
Publish date: Mon, 07 Oct 2024, 09:37 AM
rhbinvest
0 4,336
An official blog in I3investor to publish research reports provided by RHB Research team.

All materials published here are prepared by RHB Investment Bank Bhd. For latest offers on RHB Invest trading products and news, please refer to: http://www.rhbinvest.com

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur
Malaysia

Tel : +(60) 3 9280 8888
Fax : +(60) 3 9200 2216
  • Still BUY, with new DCF-derived TP of MYR3.47 from MYR3.55, 23% upside. Hartalega stands to benefit from the potential trade diversion with the latest revision of higher import tariff on China glove makers. Execution remains crucial as the recent weakening USD should be a key hindrance among investors. We continue to like the company given its solid balance sheet and improving market dynamics which should propel its FY25F (Mar) earnings. Our TP incorporates a 2% discount as HART’s ESG score is 2.9.
  • Industry dynamics remain favourable. We learnt that the industry operating dynamics have turned favourable for gloves manufacturers as customers are more receptive to the ASP increase. That said, industry blended ASP is set to improve further to USD21-22/1,000 pieces (pcs) by 4QCY24 as Malaysian glove makers are in the discussion stage to raise prices to translate the effect of the weakening USD to customers. Meanwhile, China glove makers’ ASPs now range at USD18-19/1,000 pcs from USD17-18 in the previous quarter. In terms of demand, Malaysia’s gloves export volume surged 66% MoM and 105% YoY in August, outpacing the growth in July (+12% MoM; +43% YoY). The latest export volume is even 34% higher compared to the pre-pandemic’s 2-year monthly average number, indicating that the recovery momentum of global gloves demand remains healthy.
  • US tariff on China. To recap, The Office of the United States Trade Representative (USTR) announced the final modifications concerning the statutory review of tariff actions on China, entailing a new set tariff rate on medical/surgical gloves, which will be revised to 50% and 100% (effective 2025 and 2026) from 25% effective 2026 as proposed in May. We expect HART to benefit from the potential trade diversion with estimated net earnings accretion of 5-9% in FY25-26 based on our estimate.
  • Earnings revision and valuation. We lower our FY25F-26F earnings by 21-37% largely reflecting the impact of the weakening USD against the MYR. Our USD/MYR assumptions for FY25-26 are lowered to 4.33 and 4.00 from 4.55- 4.50. For every 5% changes in USD/MYR, the impact to HART’s FY25F-26F net earnings is 26% and 23%. We believe this impact could be mitigated by gloves manufacturers raising ASP given the weakening USD (as most of them are already in the discussion stage with customers to raise prices by at least USD1). HART’s valuation remains compelling, trading at +0.9SD from its 2-year historical mean. Post earnings adjustment, we derive our new a TP of MYR3.47, representing 2.5x 2025F P/BV, or +2SD from its 2-year historical mean. Key risks: Decrease in gloves ASP, slower-than-expected capacity expansion, lower-than-expected utilisation rate, and higher-than-expected raw material prices.

Source: RHB Research - 7 Oct 2024

Related Stocks
Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment